Cover Image
市場調查報告書

孤核受體γ(RORγ):開發平台分析

Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 359830
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
Back to Top
孤核受體γ(RORγ):開發平台分析 Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Review, H1 2016
出版日期: 2016年05月18日 內容資訊: 英文 97 Pages
簡介

本報告提供以孤核受體γ(RORγ)為標的的藥物適應症,開發階段,作用機制,給藥途徑及各分子類型分析,藥物的藥理作用之相關記述,並彙整迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

孤核受體γ(RORγ)概要

治療藥的開發

孤核受體γ(RORγ):開發中的產品 - 各開發階段

孤核受體γ(RORγ):開發中的產品 - 治療範圍別

孤核受體γ(RORγ):開發中的產品 - 各適應症

孤核受體γ(RORγ):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

孤核受體γ(RORγ):企業開發中的產品

孤核受體γ(RORγ):大學/機關開發中的產品

孤核受體γ(RORγ):治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

孤核受體γ(RORγ)的治療藥開發企業

  • 4SC AG
  • Advinus Therapeutics Ltd.
  • Arrien Pharmaceuticals, LLC
  • Aurigene Discovery Technologies Limited
  • Biogen, Inc.
  • Brickell Biotech, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Genentech, Inc.
  • Genfit SA
  • GlaxoSmithKline Plc
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Karo Bio AB
  • Lead Pharma Holding B.V.
  • Nuevolution AB
  • Phenex Pharmaceuticals AG
  • Reata Pharmaceuticals, Inc.
  • TEIJIN FIBERS製藥
  • Visionary Pharmaceuticals, Inc.
  • Vitae Pharmaceuticals, Inc.

藥物簡介

孤核受體γ(RORγ):暫停中的計劃

孤核受體γ(RORγ):開發中止的產品

孤核受體γ(RORγ):主要消息和新聞稿

附錄

目錄
Product Code: GMDHC0036TDB

Summary

Global Markets Direct's, 'Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Review, H1 2016', provides in depth analysis on Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted pipeline therapeutics.

The report provides comprehensive information on the Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC)
  • The report reviews Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) Overview
    • Therapeutics Development
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Stage of Development
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Therapy Area
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Indication
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Companies
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Universities/Institutes
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Companies Involved in Therapeutics Development
    • 4SC AG
    • Advinus Therapeutics Ltd.
    • Arrien Pharmaceuticals, LLC
    • Aurigene Discovery Technologies Limited
    • Biogen, Inc.
    • Brickell Biotech, Inc.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Genentech, Inc.
    • Genfit SA
    • GlaxoSmithKline Plc
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Karo Bio AB
    • Lead Pharma Holding B.V.
    • Nuevolution AB
    • Phenex Pharmaceuticals AG
    • Reata Pharmaceuticals, Inc.
    • Teijin Pharma Limited
    • Visionary Pharmaceuticals, Inc.
    • Vitae Pharmaceuticals, Inc.
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Drug Profiles
    • ARN-6039 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BBI-6000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2981278 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INV-17 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize ROR-Gamma for Inflammation and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize RAR-Related Orphan Receptor Gamma for Psoriasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize ROR-Gamma for Multiple Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit RORgammat for CNS, Autoimmune and Gastrointestinal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize RAR-Related Orphan Receptor Gamma for Autoimmune Disorders and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize ROR gamma for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize ROR-Gamma for Autoimmune Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize ROR-Gamma for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize ROR-Gamma T for Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize RORC for Multiple Sclerosis, Immunology and Non-Alcoholic Steatohepatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit ROR gamma-t for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit ROR-Gamma for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit ROR-Gamma T for Autoimmune Disorders and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target ROR Gamma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target ROR gamma for Autoimmune Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SR-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TGFTX-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TMP-778 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPR-66 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTP-43742 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Dormant Projects
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Discontinued Products
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Featured News & Press Releases
    • Mar 16, 2016: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis
    • Nov 18, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742
    • Nov 03, 2015: Lycera Announces Progress in Immuno-Oncology Program to be Presented at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting
    • Nov 02, 2015: Lead Pharma Achieves first Milestone for Development of Autoimmune Diseases Treatments in Research Collaboration with Sanofi
    • Sep 29, 2015: Vitae Pharmaceuticals Initiates Second Part of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Psoriatic Patients
    • Sep 08, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From Initial Phase 1 Study of First-in-Class RORyt Inhibitor VTP-43742 in Autoimmune Disorders
    • Aug 10, 2015: Vitae Pharmaceuticals Announces Initiation of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Autoimmune Disorders
    • Aug 05, 2015: Aurigene to Present its RORg Inverse Agonist Program at World Congress on Inflammation, 2015
    • Jun 29, 2015: Vitae Pharmaceuticals Announces Initiation of a Phase 1 Single Ascending Dose Study of VTP-43742 in Autoimmune Disorders
    • Apr 16, 2015: Vitae Pharmaceuticals to Present at Keystone Symposia on Mechanisms of Pro-Inflammatory Diseases
    • Mar 17, 2015: New Compound Prevents Type 1 Diabetes in Animal Models-Before It Begins
    • Feb 09, 2015: Lycera Announces Research Showing Promising Anti-Cancer Activity of Novel, Oral Immunotherapy Candidates
    • Jan 05, 2015: Lycera Scientists Identify Endogenous Agonists for ROR that control Th17 Cell Differentiation
    • Nov 07, 2014: Lycera Announces Research Showing Novel, Oral Immunotherapy Possesses Potent Single Agent Anti-Cancer Activity
    • Nov 05, 2014: Innovimmune to Present Superior Preclinical Therapeutic Efficacy Results in Rheumatoid Arthritis of Its INV-17 ROR Gamma t Inhibitor Program at the 2014 American College of Rheumatology Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by 4SC AG, H1 2016
  • Pipeline by Advinus Therapeutics Ltd., H1 2016
  • Pipeline by Arrien Pharmaceuticals, LLC, H1 2016
  • Pipeline by Aurigene Discovery Technologies Limited, H1 2016
  • Pipeline by Biogen, Inc., H1 2016
  • Pipeline by Brickell Biotech, Inc., H1 2016
  • Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Pipeline by Celgene Corporation, H1 2016
  • Pipeline by Genentech, Inc., H1 2016
  • Pipeline by Genfit SA, H1 2016
  • Pipeline by GlaxoSmithKline Plc, H1 2016
  • Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Pipeline by Karo Bio AB, H1 2016
  • Pipeline by Lead Pharma Holding B.V., H1 2016
  • Pipeline by Nuevolution AB, H1 2016
  • Pipeline by Phenex Pharmaceuticals AG, H1 2016
  • Pipeline by Reata Pharmaceuticals, Inc., H1 2016
  • Pipeline by Teijin Pharma Limited, H1 2016
  • Pipeline by Visionary Pharmaceuticals, Inc., H1 2016
  • Pipeline by Vitae Pharmaceuticals, Inc., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) Overview
  • Therapeutics Development
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Stage of Development
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Therapy Area
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Indication
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Products Glance
  • Late Stage Products
  • Early Stage Products
  • Unknown Stage Products
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Companies
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Products under Development by Universities/Institutes
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Therapeutics Assessment
  • Assessment by Monotherapy/Combination Products
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Companies Involved in Therapeutics Development
  • 4SC AG
  • Advinus Therapeutics Ltd.
  • Arrien Pharmaceuticals, LLC
  • Aurigene Discovery Technologies Limited
  • Biogen, Inc.
  • Brickell Biotech, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Genentech, Inc.
  • Genfit SA
  • GlaxoSmithKline Plc
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Karo Bio AB
  • Lead Pharma Holding B.V.
  • Nuevolution AB
  • Phenex Pharmaceuticals AG
  • Reata Pharmaceuticals, Inc.
  • Teijin Pharma Limited
  • Visionary Pharmaceuticals, Inc.
  • Vitae Pharmaceuticals, Inc.
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Drug Profiles
  • ARN-6039 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BBI-6000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GSK-2981278 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INV-17 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize ROR-Gamma for Inflammation and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize RAR-Related Orphan Receptor Gamma for Psoriasis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize ROR-Gamma for Multiple Sclerosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit RORgammat for CNS, Autoimmune and Gastrointestinal Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize RAR-Related Orphan Receptor Gamma for Autoimmune Disorders and Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize ROR gamma for Breast Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize ROR-Gamma for Autoimmune Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize ROR-Gamma for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize ROR-Gamma T for Autoimmune Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize RORC for Multiple Sclerosis, Immunology and Non-Alcoholic Steatohepatitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ROR gamma-t for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ROR-Gamma for Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ROR-Gamma T for Autoimmune Disorders and Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Target ROR Gamma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Target ROR gamma for Autoimmune Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SR-1001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TGFTX-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TMP-778 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VPR-66 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VTP-43742 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Dormant Projects
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Discontinued Products
  • Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Featured News & Press Releases
  • Mar 16, 2016: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis
  • Nov 18, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742
  • Nov 03, 2015: Lycera Announces Progress in Immuno-Oncology Program to be Presented at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting
  • Nov 02, 2015: Lead Pharma Achieves first Milestone for Development of Autoimmune Diseases Treatments in Research Collaboration with Sanofi
  • Sep 29, 2015: Vitae Pharmaceuticals Initiates Second Part of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Psoriatic Patients
  • Sep 08, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From Initial Phase 1 Study of First-in-Class RORyt Inhibitor VTP-43742 in Autoimmune Disorders
  • Aug 10, 2015: Vitae Pharmaceuticals Announces Initiation of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Autoimmune Disorders
  • Aug 05, 2015: Aurigene to Present its RORg Inverse Agonist Program at World Congress on Inflammation, 2015
  • Jun 29, 2015: Vitae Pharmaceuticals Announces Initiation of a Phase 1 Single Ascending Dose Study of VTP-43742 in Autoimmune Disorders
  • Apr 16, 2015: Vitae Pharmaceuticals to Present at Keystone Symposia on Mechanisms of Pro-Inflammatory Diseases
  • Mar 17, 2015: New Compound Prevents Type 1 Diabetes in Animal Models-Before It Begins
  • Feb 09, 2015: Lycera Announces Research Showing Promising Anti-Cancer Activity of Novel, Oral Immunotherapy Candidates
  • Jan 05, 2015: Lycera Scientists Identify Endogenous Agonists for ROR that control Th17 Cell Differentiation
  • Nov 07, 2014: Lycera Announces Research Showing Novel, Oral Immunotherapy Possesses Potent Single Agent Anti-Cancer Activity
  • Nov 05, 2014: Innovimmune to Present Superior Preclinical Therapeutic Efficacy Results in Rheumatoid Arthritis of Its INV-17 ROR Gamma t Inhibitor Program at the 2014 American College of Rheumatology Annual Meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by 4SC AG, H1 2016
  • Pipeline by Advinus Therapeutics Ltd., H1 2016
  • Pipeline by Arrien Pharmaceuticals, LLC, H1 2016
  • Pipeline by Aurigene Discovery Technologies Limited, H1 2016
  • Pipeline by Biogen, Inc., H1 2016
  • Pipeline by Brickell Biotech, Inc., H1 2016
  • Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Pipeline by Celgene Corporation, H1 2016
  • Pipeline by Genentech, Inc., H1 2016
  • Pipeline by Genfit SA, H1 2016
  • Pipeline by GlaxoSmithKline Plc, H1 2016
  • Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Pipeline by Karo Bio AB, H1 2016
  • Pipeline by Lead Pharma Holding B.V., H1 2016
  • Pipeline by Nuevolution AB, H1 2016
  • Pipeline by Phenex Pharmaceuticals AG, H1 2016
  • Pipeline by Reata Pharmaceuticals, Inc., H1 2016
  • Pipeline by Teijin Pharma Limited, H1 2016
  • Pipeline by Visionary Pharmaceuticals, Inc., H1 2016
  • Pipeline by Vitae Pharmaceuticals, Inc., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top